Shaily Engineering Plastics Q3 FY26: Revenue up 27% to ₹251 Cr, EBITDA up 43%
Shaily Engineering Plastics reported Q3 FY26 revenue of ₹251 crore, a 27% YoY increase. EBITDA grew 43% to ₹66 crore. The company is investing ₹300-350 crore in a new Abu Dhabi facility for pen and auto-injectors, expected by Q4 FY28. Mr. Joe Kam appointed COO of Healthcare division.
The substantial investment in a new international facility in Abu Dhabi, expansion of manufacturing capacity for pen injectors, and strong financial performance indicators like revenue and EBITDA growth are material events that will significantly impact the company's future operations and market position.
The company reported strong year-on-year growth in revenue and EBITDA, along with significant margin expansion. The announcement of a new international facility and a key leadership appointment in the high-growth healthcare segment further contribute to a positive outlook.
Shaily Engineering Plastics Limited (SEPL) announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported a strong performance with revenue growing by 27% year-on-year to ₹251 crore in Q3 FY26, compared to ₹198 crore in Q3 FY25. EBITDA also saw a significant increase of 43% year-on-year, reaching ₹66 crore, with EBITDA margins expanding by 310 basis points to 26.5%.
The growth was primarily driven by the Healthcare segment, which now contributes 42% of the total revenue, doubling its share from the previous year. A key development announced was the establishment of a new manufacturing facility in Abu Dhabi for pen and auto-injectors, with an investment of AED130 million to AED150 million (approximately ₹300 crore to ₹350 crore). This facility is expected to be operational by Q4 FY28 and will increase the company's pen injector capacity to 150 million units annually from the current 80 million units.
Furthermore, Shaily Engineering Plastics announced the appointment of Mr. Joe Kam as the Chief Operating Officer of the Healthcare division, effective March 1, 2026. Mr. Kam brings over 20 years of international experience in manufacturing and operations. The company also secured two new customers for GLP-1s and signed two new contracts for pen injector manufacturing.
For the nine-month period ended December 31, 2025, revenue grew by 32% to ₹754 crore, and EBITDA increased by 76% to ₹218 crore. PAT for the nine months stood at ₹130 crore, a growth of 101% year-on-year. The company's ROCE and ROE were reported at 38.4% and 29.1% respectively as of December 31, 2025.
What to do with a filing like this
Shaily Engineering Plastics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shaily Engineering Plastics Limited. Read the original for the full detail.